Peter Deman Henny Janssen
description
Transcript of Peter Deman Henny Janssen
![Page 1: Peter Deman Henny Janssen](https://reader036.fdocuments.net/reader036/viewer/2022062409/5681474a550346895db48b7d/html5/thumbnails/1.jpg)
Peter Deman Henny Janssen
![Page 2: Peter Deman Henny Janssen](https://reader036.fdocuments.net/reader036/viewer/2022062409/5681474a550346895db48b7d/html5/thumbnails/2.jpg)
Subclinical hypothyroidism is frequently found in adults with Down syndrome.
Literature provides no evidence about whether this condition should be treated.
Diagnosis is based on laboratory measurements; symptoms are difficult to define.
![Page 3: Peter Deman Henny Janssen](https://reader036.fdocuments.net/reader036/viewer/2022062409/5681474a550346895db48b7d/html5/thumbnails/3.jpg)
The thyroid produces hormones that stimulate the metabolism.
Hypothyroidism: the thyroid does not produce enough hormones. The metabolic rate is lowered.
![Page 4: Peter Deman Henny Janssen](https://reader036.fdocuments.net/reader036/viewer/2022062409/5681474a550346895db48b7d/html5/thumbnails/4.jpg)
Normal Thyroid dysfunction practically excluded, euthyroidism
Increased Decreased hypothyroidism
Increased Normal subclinical hypothyroidism
TSH FT4 Diagnosis
![Page 5: Peter Deman Henny Janssen](https://reader036.fdocuments.net/reader036/viewer/2022062409/5681474a550346895db48b7d/html5/thumbnails/5.jpg)
Lowered metabolic rate: weight gain, cold intolerance, constipation, inactiveness, fatigue and menstrual problems.
Complaints and symptoms are not specific.
Predictive value of complaints is low.
![Page 6: Peter Deman Henny Janssen](https://reader036.fdocuments.net/reader036/viewer/2022062409/5681474a550346895db48b7d/html5/thumbnails/6.jpg)
High prevalence, 12-33%
According to international guidelines, adults with DS should be screened for thyroid function.
![Page 7: Peter Deman Henny Janssen](https://reader036.fdocuments.net/reader036/viewer/2022062409/5681474a550346895db48b7d/html5/thumbnails/7.jpg)
Prevalence of SH much lower:4-8%
No screening, and thyroid function tests only in case of complaints, according to NHG- standard.
Treatment with levothyroxine replacement when there is no other explanation for complaints and symptoms.
![Page 8: Peter Deman Henny Janssen](https://reader036.fdocuments.net/reader036/viewer/2022062409/5681474a550346895db48b7d/html5/thumbnails/8.jpg)
Subclinical hypothyroidism is frequently found in adults with Down syndrome.
Literature provides no evidence about whether this condition should be treated.
Diagnosis is based on laboratory measurements; symptoms are difficult to define.
![Page 9: Peter Deman Henny Janssen](https://reader036.fdocuments.net/reader036/viewer/2022062409/5681474a550346895db48b7d/html5/thumbnails/9.jpg)
Clinical expertise
Best research evidence
Patient’s unique values and circumstances
![Page 10: Peter Deman Henny Janssen](https://reader036.fdocuments.net/reader036/viewer/2022062409/5681474a550346895db48b7d/html5/thumbnails/10.jpg)
Knowledge ?
Experience?
Difficulties?
Questions ?
Suggestions for futher research?
![Page 11: Peter Deman Henny Janssen](https://reader036.fdocuments.net/reader036/viewer/2022062409/5681474a550346895db48b7d/html5/thumbnails/11.jpg)
44 years old Woman with Down syndrome TSH 5,3 (ref 0,4-4,0 mU/l) FT4 13 (ref 9-25 pmol/l)
![Page 12: Peter Deman Henny Janssen](https://reader036.fdocuments.net/reader036/viewer/2022062409/5681474a550346895db48b7d/html5/thumbnails/12.jpg)
Do you recognise this situation? Do you have experience with it? What is your first reaction?
How do you act in this situation?
Are there subgroups of people with DS where you act differently?
Have any aspects been left out?
![Page 13: Peter Deman Henny Janssen](https://reader036.fdocuments.net/reader036/viewer/2022062409/5681474a550346895db48b7d/html5/thumbnails/13.jpg)
Focus group
Focus group
Focus group
Focus group
![Page 14: Peter Deman Henny Janssen](https://reader036.fdocuments.net/reader036/viewer/2022062409/5681474a550346895db48b7d/html5/thumbnails/14.jpg)
Transcripts from five discussions (5278 sentences)
Key points marked (21 codes)
Grouped in concepts (six themes)
Basic categories (two categories)
Theory or conceptual framework
![Page 15: Peter Deman Henny Janssen](https://reader036.fdocuments.net/reader036/viewer/2022062409/5681474a550346895db48b7d/html5/thumbnails/15.jpg)
Diagnostic testing and interpretation of results varies according to ID-MD.
Investigation and registration of symptoms proves to be a difficult task.
Various resources of evidence; not always certain.
![Page 16: Peter Deman Henny Janssen](https://reader036.fdocuments.net/reader036/viewer/2022062409/5681474a550346895db48b7d/html5/thumbnails/16.jpg)
![Page 17: Peter Deman Henny Janssen](https://reader036.fdocuments.net/reader036/viewer/2022062409/5681474a550346895db48b7d/html5/thumbnails/17.jpg)
![Page 18: Peter Deman Henny Janssen](https://reader036.fdocuments.net/reader036/viewer/2022062409/5681474a550346895db48b7d/html5/thumbnails/18.jpg)
![Page 19: Peter Deman Henny Janssen](https://reader036.fdocuments.net/reader036/viewer/2022062409/5681474a550346895db48b7d/html5/thumbnails/19.jpg)
Most ID-MDs are reluctant to treat.
The minority of ID-MDs administer thyroid hormone until normalisation of laboratory findings.
They may feel uncertain or inadequate.
![Page 20: Peter Deman Henny Janssen](https://reader036.fdocuments.net/reader036/viewer/2022062409/5681474a550346895db48b7d/html5/thumbnails/20.jpg)
![Page 21: Peter Deman Henny Janssen](https://reader036.fdocuments.net/reader036/viewer/2022062409/5681474a550346895db48b7d/html5/thumbnails/21.jpg)
![Page 22: Peter Deman Henny Janssen](https://reader036.fdocuments.net/reader036/viewer/2022062409/5681474a550346895db48b7d/html5/thumbnails/22.jpg)
![Page 23: Peter Deman Henny Janssen](https://reader036.fdocuments.net/reader036/viewer/2022062409/5681474a550346895db48b7d/html5/thumbnails/23.jpg)
![Page 24: Peter Deman Henny Janssen](https://reader036.fdocuments.net/reader036/viewer/2022062409/5681474a550346895db48b7d/html5/thumbnails/24.jpg)
![Page 25: Peter Deman Henny Janssen](https://reader036.fdocuments.net/reader036/viewer/2022062409/5681474a550346895db48b7d/html5/thumbnails/25.jpg)
Describe and measure with validated rating scales
Study the natural history Involve patients and interest groups
Evaluate if a Randomised Controlled Trial on the effects of treatment is possible or useful
The development of guidelines will eventually become possible
![Page 26: Peter Deman Henny Janssen](https://reader036.fdocuments.net/reader036/viewer/2022062409/5681474a550346895db48b7d/html5/thumbnails/26.jpg)
Expertise and experience of ID-MD combined with the unique values and
circumstances of the patient will guide the decision-making.
![Page 27: Peter Deman Henny Janssen](https://reader036.fdocuments.net/reader036/viewer/2022062409/5681474a550346895db48b7d/html5/thumbnails/27.jpg)
Huisartsenpraktijk Berkenhove